chrisvoncsefalvay/vaers-outcomes huggingface dataset:
coming down with COVID; coming down with COVID; has not been feeling well; sore throat and chest congestion; sore throat and chest congestion; This is a spontaneous report from a contactable consumer (patient) via Pfizer. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: Unknown, Expiration date: Unknown), via an unspecified route of administration on an unspecified date as dose number unknown, single for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient was coming down with covid and experienced has not been feeling well, sore throat and chest congestion. Patient believes he was coming down with COVID. Patient was is in a clinical Trial. He was still enrolled in the clinical trial and he was told he was going to continue his trial in with a new center, however he does not have the location or phone number. Clinical Trial. He wanted someone to pick up his test kit and wanted information on that new clinical trial center. The events COVID-19 and drug ineffective considered as medically significant. The outcome of the events was unknown.  Follow up attempts are possible. Further information is expected.
Localized swelling and redness with itching left deltoid area. Benadryl and cold compresses.
Pt recvd 1st dose of Engerix-B 20NOV91 & exp a rash;
This spontaneous report was received from a medical assistant referring to a multiple, unknown patients of unknown age and gender. The patients' pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided. The medical assistant reported that, on unknown dates, the patients received improperly stored doses of VARIVAX Lot # M039316 with an expiration date on 20-SEP-2018 (dose and route of administration were not reported) for prophylaxis. No adverse effects were reported. The vaccines were stored in a temperature in the range of -9°C to 8°C (-6°C) for a total time of 18 hours. The call was because of a data logger and no previous temperature excursion was registered. This is one of two reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1705USA003934.
Severe muscle and joint pain, fever (101.5), headache, nausea, lethargy, chills, sweating
Information has been received from a physician and a licensed practical nurse concerning a 72 year old female patient with no pertinent medical history or allergies who on 22-JUN-2007 was vaccinated with a dose of ZOSTAVAX (Oka/Merck) (lot #652947/1411F). Concomitant therapy included vitamins (unspecified), LIPITOR, aspirin, METROGEL and triamcinolone topical. The nurse reported that on 23-JUN-2008, the patient developed herpes zoster on left knee to left buttock, L 4-5 distribution. The patient stated she had "unbearable pain". The same day, a viral culture was done; varicella zoster virus DNA detected and it was negative for herpes simplex type 1 and 2 DNA. The nurse was not interested in VZV Analysis by PCR. At the time of the report the patient was recovering. The patient sought medical attention at the physician's office. No further information is available.
Information has been received from a nurse practitioner concerning a patient who was vaccinated with the first dose of varicella virus vaccine live (Oka/Merck) and developed a case of chickenpox a couple of years later. The patient recovered from the chickenpox on an unknown date. Unspecified medical attention was sought. No product quality complaint was involved. Additional information is not expected.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Physician).  A 36-year-old male patient received BNT162b2 (BNT162B2), on 26Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 36 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Obesity" (unspecified if ongoing); "asthma" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Amoxicillin, reaction(s): "Known allergies: Amoxicillin". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (May2022) Positive, notes: On Day 7. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on reported information, causal association of event drug ineffective, covid-19 with BNT162b2 cannot be excluded. However, response to vaccine can vary in individuals.
At 24-36 hours, pain, swelling at injection site. Low grade temperature 99 degree to 100 degree. Myalgias, malaise.  At 48 hours with squamous erythema, edema, induration. Maximum diameter about 10cm. Axillary pain and fullness. No palpable discrete lymphadenopathy.
Patient reported that later in the evening she had difficulty breathing and ended up going to the emergency room. When being asked about medical history, she indicated she received a shingles vaccination that morning. The patient did not elaborate much more other than the ER indicated that that may be a side effect from the shot. Patient would not elaborate on the reaction much more than this.
Site: Pain at Injection Site-Medium, Systemic: Other- Pain radiating from neck to deltoid "in a line." Patient believes immunizer had good technique and doesn't believe the shot was given too high on the arm. Medium; symptoms lasted 21 days.
Seen in ER and evaluated for chest pain and difficulty breathing. Lungs clear, fever of 104F. Abnormal EKG but cardiac enzymes normal. Received breathing treatment which helped. Released with a DX of bronchitis; treated with antibiotic and inhaler. Felt ill X 7 days. Repeat X-ray, 2 1/2-3 weeks later, was normal.
Rec'd on 5/19/11 Tdap and Varicella vaccines. Presents today with c/o redness and swelling at site of Varicella. Tdap injection site not involved. Noted moderate swelling and 50mm x 50mm area of redness around injection site. Has been using ice packs, Ibuprofen, etc.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose01/7/21 2nd dose01/28/21 Diagnosed covid positive:08/16/21 Symptom onset:08/16/21 Exposure:Home Symptoms:fever, fatigue,muscle aches,loss of smell/taste, nausea, HA
Fell back and had 3-4 arm/legs jerking movements, right after getting the HPV vaccine.
Pt received Td vaccination booster IM right deltoid on 01/10/2001. She was seen on 01/12/2001 at the clinic, reporting that she had been dizzy, nauseous, and feverish since shortly after receiving the vaccine. Injection site was red and sore to the touch. She was encouraged to increase fluids and to take advil. On 01/16/2001 the symptoms had resolved.
Skin rash developed 9 days after MMR dose 1 was administered. Afebrile. Has been fussy, seems itchy. Treated w/ Benadryl
chills, muslce aches, joint pain/stiffness, headache - all extreme; I did have COVID-19 about 7 weeks ago
No adverse reactions reported. Mixing error when reconstituting the vaccine. Only 0.8ml of diluent was used instead of 1.8ml.
Information has been reported in a CDC slide titled as "Safety of PNEUMOVAX 23 in the Vaccine Adverse Reporting System (VAERS)". This spontaneous prospective pregnancy report as received from a registered nurse (RN) in Centers for Disease Control and Prevention (CDC) concerning a female patient of unknown age, 2 of the four patients who experienced no adverse event. On an unknown date, the patient became pregnant. The last menstrual period (LMP) and estimated date of delivery (EDD) was not known. On an unknown date the patient was administered with a dose of PNEUMOVAX 23 (lot#, dose and route were unspecified) during pregnancy. No adverse event reported. The outcome of pregnancy was unknown. The pregnancy outcome was unknown. This is one of the 18 reports (PNEUMOVAX 23 administered during pregnancy) that received from the same source. Additional information has been requested.
Burning in both right and left feet; Tingling in both right,left feet and hands; Local burning sensation in thighs; Numbness in left little finger, 5th digit; This is a spontaneous report from a non contactable consumer, the patient. A 48-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EL9269) via an unspecified route of administration on an unknown date in Feb2020 (at the age of 48-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On an unknown date in Feb2020 the patient experienced burning in both right and left feet, tingling in both right, left feet and hands, local burning sensation in thighs and numbness in left little finger. No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of burning in both right and left feet, tingling in both right, left feet and hands, local burning sensation in thighs and numbness in left little finger was unknown at the time of this report.
having  a fever of 101.3; This case was reported by a physician via call center representative and described the occurrence of fever in a 50-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, 36 hrs after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was unknown.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows:  The age at vaccination was not reported. The reporter was patient itself. The patient had fever of 101.3 degree F. The reporter consented to follow up.
"Sharp chest pain beginning 4 days after vaccine, happened after 1st dose as dull aching in chest"; This is a spontaneous report from a non-contactable consumer, the patient. This is first of the two reports. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the right arm on 27Mar2021 (at the age of 18-years-old) as dose 1, single for COVID-19 immunisation. The patient had no medical history and no known allergies to medications, food or other products. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 12May2021 at 19:15 (at the age of 19-years-old) as dose 2, single for COVID-19 immunisation. The patient received BCP (Birth Control Pill) within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient experienced sharp chest pain beginning 4 days after vaccine, it happened after first dose as dull aching in chest, but resolved in 2 hours. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event sharp chest pain beginning 4 days after vaccine, happened after first dose as dull aching in chest was recovered on 31Mar2021. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Three weeks after second vaccine dose started with intermittent severe pain in legs and then became constant. Pain went back to intermittent with numbness and tingling and pain in feet. After a few days the numbness and pain went to hands. then ascended a few days later to month and inside of nose.  These symptoms still remain today after 10 months. On Gabapentin 600mg TID for pain.
Pt recvd vax & 48 hrs p/vax devel a red, raised rash, w/pruritic areas (1/2 cm in daimeter) which began on upper arms & thigh & spread to entire body; devel flu-like sx;
A physician reported that a 7 year old male, post vax, developed a fever of 104 to 105F, chills, body aches, cough and nasal drainage. A dx of influenza was made; however, the type was not specified.
a small ball in the arm at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (a small ball in the arm at injection site) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 20-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced VACCINATION SITE SWELLING (a small ball in the arm at injection site). At the time of the report, VACCINATION SITE SWELLING (a small ball in the arm at injection site) outcome was unknown. Not Provided          Action taken with mRNA-1273 in response to the event was not applicable. No concomitant medication information was provided. No treatment product information was provided.
product - COVID 19 Treatment; product - COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Nov2021 as dose 2 (booster), single (Batch/Lot number: unknown) at the age of 59 years, in left arm for covid-19 immunisation; janssen coviD-19 vaccine (JANSSEN COVID-19 VACCINE), on 07Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "product - COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (17May2022) Positive, notes: positive antigen tests. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report as received from a physician via a company representative and refers to a female patient of unknown age. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 14-AUG-2013, the patient was vaccinated with the first dose of GARDASIL (dose, route and site of administration, lot # and expiration date were not reported). On an unknown date in January 2014 (reported as 5 month after vaccination), the patient was diagnosed with neuromyelitis optica. There was no 2nd or 3rd vaccination administered. The patient sought unspecified medical attention. The outcome of neuromyelitis optica was reported as not recovered/not resolved at the time of the report. The relatedness between the event and GARDASIL was not reported by the physician, however the patient's mother believed it was because of GARDASIL since symptoms began after vaccination. Upon internal review, the event of neuromyelitis optica was considered to be medically significant. Additional information has been requested.
Soon after receiving the vaccine she started getting a terrible headache, migraine like.  Within 2 hours of receiving the vaccine her nose swelled and she was unable to breathe out of it, her lips swelled, and her tongue felt swollen.  Swelling improved by the next day.  She also had bad muscle spasms in her legs, arms, and hips which hurt for 2 days.
No signs or symptoms reported; VARlVAX was administered to four patient; This spontaneous report was received from a medical assitant refers to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions and concomitant medications were not provided.       On 01-SEP-2021, the patient was vaccinated with an improper stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot number U002400, expiration date 22-JAN-2023 (dose and route of administration not provided) for prophylaxis. No adverse event was reported.  The vaccine underwent a temperature excursion of -13 dregrees Celsius for 1 hour and 30 minutes. There were no previous temperature excursions.  This is one of four cases reported by the same reporter.
Insomnia, nerve pain in ears and legs, headache, fatigue after the insomnia, chills.
Information has been received from a health professional concerning a 69 year old female with penicillin, codeine and sertraline hydrochloride allergies who on approximately 1/14/04 was vaccinated IM with a second dose of pneumococcal 23v polysaccharide vaccine (lot # 647724/0946N). There was no illness at the time of vaccination. Concomitant therapy included simvastatin 10mg PO QD, alendronate sodium 70mg PO Q week, vitamin E 400U PO QD, calcium (+) vitamin D 1200mg/400iu PO BID, Nefazodone HCl 75mg PO BID, hydroxyzine hydrochloride 25mg PO QD and tolterodine tartrate 4mg PO QD. Subsequently, the patient developed a local reaction which included temporary loss of full use of the arm, pain, erythema and hardness which as reported to be bothersome to the patient. On 1/16/04, the patient was seen by the physician for redness and pain in her arms. Her physical exam showed that she had a fourteen centimeter streak down towards her antecubital fossa by her basilic vein with a little warmth to it. There was no redness in the hand and no evidence of contiguous infection anywhere in the arms, including her injection site. The physician's assessment was phlebitis in the arm, etiology which was undetermined. Treatment with cephalexin 500mg QID for 7 days and then some naproxen 500mg bid was ordered. The physician also recommended using hot packs. Subsequently the patient recovered. There was no product quality complaint involved. It was also noted that 2 other patients were vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot # 647724/0946N) and had similar experiences. It was noted that all the reactions came from the same lot number but upon inspection the vaccine appears to be fine. No further information is expected.
Patient received 7 vaccines in both arms on 4/27/2006.  His mother called the Call Center at 3PM on 4/28/2006 because of redness and swelling on both arms.  She was directed to take her son to the ER.  According to the mother the ER physician stated that patient had cellulitis of both arms due to the amount of vaccine given.  Patient was given a Rx of Augmentin.  ON 5/1/2006 Mom called the State Health Services (DSHS) to register a complaint.  DSHS directed her to contact VAERS and they contacted me on 5/2/2006.  I called Mom on 5/2/2006 and she gave me above information.  I contacted VAERS on 5/2/2006 and asked for a copy of the report. At this time, I have unable to secure an ER report.
Excruciating right glenohumeral (shoulder) joint pain -- no muscle pain, along with greatly restricted range of motion.  It is apparent that the hypodermic needle punctured the rotator cuff and bottomed out onto bone ("twinge" felt upon point of full insertion and upon injection).  The injection site was too high on the upper arm (just below the subacromial space - I have photos with the location marked).  Additionally, the 1-1/2 inch long hypodermic needle was fully inserted without manipulating the muscle to raise its height.  The above was confirmed by examination by Doctor.         Pain and diminished range of motion still evident, but somewhat subsiding as of 11:00PM 2-15-2021 (55 hours after onset).
This case was reported by a healthcare professional and described the occurrence of vomiting in an infant subject of unspecified gender who was vaccinated with ROTARIX (GlaxoSmithKline). On an unspecified date, within the past four years the subject received unspecified dose of ROTARIX (oral). At an unspecified time after vaccination with ROTARIX the subject experienced vomiting. The infant subject vomited after receiving a dose of ROTARIX. The healthcare professional did not have specific details about the vomiting incident because it occurred in the past. At the time of reporting the outcome of the vomiting was unspecified. The healthcare professional reported another case, please see A1025910A.
it hurts a little bit more; it looks like there is a big, red area around the shot; the area was very sore/ it is swelling up; it looks like there is a big, red area around the shot; the area was very sore; it looks like there is a big, red area around the shot; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administered in arm, administration date 24Sep2021 (Lot number: 30135BA) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, LOT: EN2003), administration date: 26Feb2021, for COVID-19 immunization; Bnt162b2 (DOSE 2, SINGLE, LOT:  ER2613), administration date: 28Mar2021, for COVID-19 immunization, reaction(s): "Tiredness". The following information was reported: PAIN (non-serious) with onset 24Sep2021, outcome "not recovered", described as "it hurts a little bit more"; VACCINATION SITE SWELLING (non-serious) with onset 24Sep2021, outcome "not recovered", described as "it looks like there is a big, red area around the shot; the area was very sore/ it is swelling up"; VACCINATION SITE PAIN (non-serious) with onset 24Sep2021, outcome "not recovered", described as "it looks like there is a big, red area around the shot; the area was very sore"; VACCINATION SITE ERYTHEMA (non-serious) with onset 24Sep2021, outcome "not recovered", described as "it looks like there is a big, red area around the shot".  No follow-up attempts are possible. No further information is expected.
pt sat down after 15 minutes of getting imz then left....about 10 minutes after that pt came back and said he was not feeling well and holding his chest he said he had chest pain.....also complained of being hot, faint, and sweaty........we got cold compress for him.......pt was yawning and closed eyes....he wanted to lie down and we allowed him to do that....we got cold compress for him.........after 15 min he sat back up and we gave him water and took bp 123/71 HR 58.......temp 97.4......he said he felt better and left.
Six days after receiving th booster I fainted and had to go to the ER for head injury. I have never fainted before in my entire life.  We have a daughter who also fainted six days after receiving her Pfizer Covid booster shot.  She had never fainted before in her entire life.  She is 53 years old.
Stomach bloating, acid reflux, vomiting, indigestion  Symptoms have been occurring since approximately a week and a half following the 2nd Moderna vaccination up to current (3/23/2022) today's date.